Search PubMed⌕ Search

Biomedical subjects

P Krieg

Publications and source records attributed to P Krieg.

63 records · Page 4Linked to original sources
PubMed1981

Experimental reversal of acute coronary thrombotic occlusion and myocardial injury in animals utilizing streptokinase.

Fresh autologous thrombus, 1.0 to 1.5 ml, was injected into the left anterior descending and/or left diagonal coronary arteries of 19 open-chest dogs to produce evolving acute myocardial infarction (AMI). Thrombotic obstruction was documented by coronary angiography. Multilead epicardial ECGs showed ST segment elevations of affected left ventricular (LV) areas within 2 minutes after thrombus injection, and LV segmental wall cyanosis with hypocontraction was observed within 10 minutes in the myocardial areas supplied by the thrombosed artery. Ten animals then received an initial dose of streptokinase (STK), 250,000 U (intravenous), followed by STK, 1000 to 3000 U/min (intracoronary), while nine control dogs untreated with STK received normal saline infusion. All but one STK-treated animal (all nine animals receiving intracoronary STK) had reestablishment of blood flow in the previously occluded vessels within 1 1/2 hours, disappearance of ventricular cyanosis, return of normal LV contractile function, and normalization of elevated ST segments within 1 hour after intracoronary STK therapy. In contrast, in the non-STK-treated control group, all animals had continued coronary obstruction, progressive ST elevations, and worsening LV cyanosis and hypocontraction until death or for more than 3 hours post thrombus; three control animals died of ventricular fibrillation (VF) within 1 hour of thrombus occlusion, three more died of VF within 2 hours post thrombus, and only three survived beyond 2 hours post thrombus. Postmortem examination of non-STK-treated animals revealed extensive residual coronary thrombus. All intracoronary STK-treated animals evidenced absence of residual coronary thrombus at postmortem examination. These data provide clinically relevant evidence that early intracoronary STK effects thrombolysis in AMI by reopening coronary vessels occluded by fresh thrombus, thereby protecting myocardium from further ischemia and necrosis, preserving LV function, and also reversing cardiac muscle injury.

Animals↗
PubMed1981

Episomal simian virus 40 genomes in human brain tumors.

Eight out of 35 human intracranial tumors were shown by restriction enzyme analysis to contain unintegrated simian virus 40 (SV40) DNA molecules. The relative amount of viral DNA was estimated to be the equivalent of one viral genome within every 10th to 20th cell. No infectious virus was detected in tissue cultures established from the tumors. From only one tumor was it possible to rescue, by cell fusion, infectious SV40 displaying wild-type properties. In those cases that permitted a more detailed analysis, the restriction enzyme cleavage patterns appeared to correspond to the wild-type patterns with one exception, in which the SV40 episomes displayed a deletion of approximately 70 base pairs close to the origin of DNA replication. From one tumor, the SV40 genomes were transferred into permissive CV-1 monkey cells by transfection with the total tumor DNA. Despite their persistence as episomes no infectious virus was produced. Furthermore, no viral antigens were detectable, although the SV40 messengers for the small and the large tumor antigens were present. These cells had, however, acquired the ability to form colonies in low concentrations of serum. Thus this report provides, by restriction enzyme analysis, direct evidence for the presence of SV40 DNA in human tumors.

Base Sequence↗
PubMed1980

Growth dynamics of a latent primate papovavirus.

The stumptailed macaque papovavirus strain HD was discovered in a persistently infected cell line of primate origin designated Vero 76 (K. Bosslet and G. Sauer, J. Virol. 25:596--607, 1978; W. Waldeck and G. Sauer, Nature [London] 269:171--173, 1977). In clonal derivatives of Vero 76 cells a minor and variable proportion of cells is engaged in the productive synthesis of the HD virus strain. A combination of immunofluorescence using simian virus 40 polyoma subgroup-specific antiserum and in situ hybridization with HD complementary RNA revealed that only those cells which harbor discernible amounts of HD DNA also contain the subgroup-specific antigen. Treatment with arabinofuranosylcytosine caused irreversible disappearance of the antigen, whereas actinomycin D, in contrast, reversibly inhibited both HD DNA replication and synthesis of the subgroup-specific antigen. The proportion of HD DNA and subgroup-specific antigen-synthesizing cells in Vero 76 clonal lines could be either decreased or increased by the mode of passaging of the cell cultures. When cell cultures were split every 3 to 7 days at a 1:4 ratio, the amount of HD DNA sequences as revealed by DNA-DNA reassociation and by the Southern blotting technique fell below the level of detection after only a few passages. Furthermore, expression of the viral subgroup-specific antigen was no longer discernible. However, viral DNA persists in such latently infected cells, because a change in the splitting protocol to a 2-week passaging rhythm led to reinitiation of both viral DNA replication and expression of the subgroup-specific antigen. The HD DNA is perpetuated in a restricted state in latently infected cells in an episomal, unintegrated form as shown by Southern blot analysis. This finding complies with the fact that HD DNA-free subclones could be derived from persistently infected clonal Vero 76 cells. Such subclones have lost the viral genomes, probably owing to segregation during cell division.

Animals↗
PubMed1979

Histone genes are clustered with a 15-kilobase repeat in the chicken genome.

Histone mRNA isolated from 5-day-old chick embryos has been used as a template for complementary DNA (cDNA) synthesis. The resultant cDNA, after removal of sequences complementary to rRNA, was used to detect histone genes in adult chicken genomal DNA. Hybridisation data indicate that the histone genes are repeated about 10-fold in the chicken genome. Restriction endonuclease analysis reveals some sequence heterogeneity in these genes. However, the results show that chicken histone genes are clustered with a basic repeat unit of 15 kilobases.

Alleles↗
PubMed1976

The distirubtion of active genes (globin) and inactive genes (keratin) in fractionated chicken erythroid chromatin.

Repeatable fractionation of sheared chromatin from purified populations of chicken erythroid cells has been achieved, based on the Bio-Gel procedure of Janowski et al. ((1972) Karolinska Symp. 5, 112). For reticulocytes, 3-5% of chromatin DNA is excluded from Bio-Gel A-50 m (peak I) and over 90% elutes in the included volume of the column(peak II). Peak I material has a higher protein/DNA ratio than peak II chromatin and the two fractions have melting profiles characteristic of "active" and "inactive" chromatin, respectively. In cells prelabeled with [3H]uridine or [3H]leucine there was very pronounced preferential association of radioactivity with the "active" peak I chromatin. The distribution of "active" (globin) and "inactive" (keratin) gene sequences in the DNA of fractions from peak I and peak II chromatin was determined with complimentary DNA (cDNA) probes to chicken globin mRNA and chicken feather keratin mRNA. While slight enrichment for globin gene sequences was found in peak I (relative to DNA in these fractions), some 80% of the total globin hybrid formed was found in peak II fractions. Experiments with the keratin cDNA probe showed that these genes were equally distributed in both chromatin fractions rather than being confined to the "inactive" peak II material. The hybridization data in particular question the validity of claims for fractionation of chromatin into "active" and "inactive" material.

Anemia↗
PubMedDate not supplied

Efficacy of acebutolol in chronic stable angina using single-blind and randomized double-blind protocol.

The clinical effects of a cardioselective beta-adrenergic blocking drug, acebutolol, were studied in 25 patients with chronic stable angina, using a seven-week single-blind placebo leads to acebutolol (mean dose 913 mg/day) phase followed by 12-week randomized double-blind placebo leads to acebutolol (mean dose 968 mg/day) crossover protocol. Objective parameters from exercise treadmill tests showed consistent reduction in resting and maximal exercise heart rate and rate-pressure product during both single- and double-blind phases. Duration of exercise and maximal ST segment depression were not significantly altered. Subjective improvement following acebutolol was observed with reduced frequency of anginal attacks and nitroglycerin consumption during the single-blind phase. However, no differences were seen during the double-blind phase due to significant subjective improvement during the latter placebo period. Adverse effects observed were mild in nature and were similar to those seen with other beta blockers. These data establish acebutolol as a potent beta-blocking agent and emphasize the importance of utilizing objective parameters over subjective variables in demonstrating the clinical antianginal efficacy of a beta blocker.

Acebutolol↗